Notables from Sinovac's (SVA) financial results: 1) stripping out 2011 Panflu sales related to the government's stockpiling program, Q4 and FY12 sales rose 166.9% and 38.6% respectively; 2) success in Phase III clinicals for EV71 vaccine made 2012 a "transformative year" for the company; 3) growth in sales of core products (Healive, Bilive, Anflu) "very" pleasing. SVA also says Mexican regulators have approved the commercialization of the seasonal flu vaccine. Shares +1.2% premarket.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs